These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 34764663)

  • 1. Acarbose Reduces Low-Grade Albuminuria Compared to Metformin in Chinese Patients with Newly Diagnosed Type 2 Diabetes.
    Song L; Kong X; Yang Z; Zhang J; Yang W; Zhang B; Chen X; Wang X
    Diabetes Metab Syndr Obes; 2021; 14():4451-4458. PubMed ID: 34764663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin or Acarbose Treatment Significantly Reduced Albuminuria in Patients with Newly Diagnosed Type 2 Diabetes Mellitus and Low-Grade Albuminuria.
    Pan Q; Xu Y; Yang N; Gao X; Liu J; Yang W; Wang G
    Med Sci Monit; 2018 Dec; 24():8941-8949. PubMed ID: 30531690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Acarbose and Metformin on Albumin Excretion in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial.
    Pan Q; Xu Y; Yang N; Gao X; Liu J; Yang W; Wang G
    Medicine (Baltimore); 2016 Apr; 95(14):e3247. PubMed ID: 27057866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials.
    van der Aart-van der Beek AB; van Raalte DH; Guja C; Hoogenberg K; Suchower LJ; Hardy E; Sjöström CD; Heerspink HJL
    Diabetes Obes Metab; 2020 Sep; 22(9):1556-1566. PubMed ID: 32329160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with improvement in waist-to-height ratio among newly diagnosed type 2 diabetes patients treated with acarbose or metformin: A randomized clinical trial study.
    Song LL; Wang X; Yang ZJ; Kong XM; Chen XP; Zhang B; Yang WY
    World J Diabetes; 2020 Nov; 11(11):514-526. PubMed ID: 33269063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of acarbose and metformin on the inflammatory state in newly diagnosed type 2 diabetes patients: a one-year randomized clinical study.
    Mo D; Liu S; Ma H; Tian H; Yu H; Zhang X; Tong N; Liao J; Ren Y
    Drug Des Devel Ther; 2019; 13():2769-2776. PubMed ID: 31496653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different Interactive Effects of Metformin and Acarbose With Dietary Macronutrient Intakes on Patients With Type 2 Diabetes Mellitus: Novel Findings From the MARCH Randomized Trial in China.
    An Y; Li Y; Bian N; Ding X; Chang X; Liu J; Wang G
    Front Nutr; 2022; 9():861750. PubMed ID: 35558742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary albumin excretion with sitagliptin compared to sulfonylurea as add on to metformin in type 2 diabetes patients with albuminuria: A real-world evidence study.
    Goldshtein I; Karasik A; Melzer-Cohen C; Engel SS; Yu S; Sharon O; Brodovicz K; Gadir N; Katzeff HL; Radican L; Chodick G; Shalev V; Tunceli K
    J Diabetes Complications; 2016; 30(7):1354-9. PubMed ID: 27320183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
    Derosa G; Salvadeo SA; D'Angelo A; Ferrari I; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
    Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MARCH2: comparative assessment of therapeutic effects of acarbose and metformin in newly diagnosed type 2 diabetes patients.
    Wang G; Liu J; Yang N; Gao X; Fan H; Xu Y; Yang W
    PLoS One; 2014; 9(8):e105698. PubMed ID: 25148570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.
    Yang HK; Lee SH; Shin J; Choi YH; Ahn YB; Lee BW; Rhee EJ; Min KW; Yoon KH
    Diabetes Metab J; 2019 Jun; 43(3):287-301. PubMed ID: 30604599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postprandial glucagon-like peptide 1 secretion is associated with urinary albumin excretion in newly diagnosed type 2 diabetes patients.
    Song LL; Wang N; Zhang JP; Yu LP; Chen XP; Zhang B; Yang WY
    World J Diabetes; 2023 Mar; 14(3):279-289. PubMed ID: 37035218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects.
    Kim S; Jang IJ; Shin D; Shin DS; Yoon S; Lim KS; Yu KS; Li J; Zhang H; Liu Y; Brendel E; Blode H; Wang Y
    J Clin Pharm Ther; 2014 Aug; 39(4):424-31. PubMed ID: 24806030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Metformin, Acarbose and Their Combination on the Serum Visfatin Level in Nicotinamide/Streptozocin-Induced Type 2 Diabetic Rats.
    Salemi Z; Rafie E; Goodarzi MT; Ghaffari MA
    Iran Red Crescent Med J; 2016 Mar; 18(3):e23814. PubMed ID: 27247792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MARCH: factors associated with weight loss in patients with newly diagnosed type 2 diabetes treated with acarbose or metformin.
    Wang N; Zhang JP; Xing XY; Yang ZJ; Zhang B; Wang X; Yang WY
    Arch Med Sci; 2019 Mar; 15(2):309-320. PubMed ID: 30899282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of glucose lowering effect of metformin and acarbose in type 2 diabetes mellitus: a meta-analysis.
    Gu S; Shi J; Tang Z; Sawhney M; Hu H; Shi L; Fonseca V; Dong H
    PLoS One; 2015; 10(5):e0126704. PubMed ID: 25961824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gender-differential effects on blood glucose levels between acarbose and metformin in Chinese patients with newly diagnosed type 2 diabetes: a sub-analysis of the MARCH trial.
    Li J; Li J; Shan Z; Yang W; Liu J; Tian H; Zhou Z; Ji Q; Weng J; Jia W; Lu J; Liu J; Xu Y; Yang Z
    Endocr J; 2021 Jan; 68(1):69-79. PubMed ID: 32908086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.